GoPro Inc vs Revvity Inc — how do they compare? GoPro Inc trades at $1.21 (market cap $243.50M), while Revvity Inc trades at $154.76 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 69.7× GoPro Inc's market cap, and Revvity Inc pays a 0.18% dividend while GoPro Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GoPro Inc for 45 Days and Revvity Inc for 12 Days on average.
| GPRO | RVTY | |
|---|---|---|
Market Cap | $243.50M | $16.98B |
Volume | 11,527,160 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $2.35 | $157.36 |
52-Week Low | $0.58 | $82.26 |
Typical Hold Time | 45 Days | 12 Days |
Enterprise Value | $302.28M | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
GoPro (GPRO) trades at $1.22, down 7.58% on the day, as the company faces significant financial challenges with negative net income margins and declining revenues. Despite recent product recognition for its MISSION 1 series, the stock has been volatile amid merger discussions with Starman Optical and influencer investment interest. Technical indicators show a bullish moving average signal but mixed oscillators, while fundamentals reveal persistent losses and cash burn.
The outlook remains highly speculative with a proposed $1.14 per share buyout offering a potential floor, but ongoing losses and competitive pressures pose substantial risks. Analyst sentiment is mixed with only 21% buy ratings, reflecting skepticism about the company's turnaround prospects despite recent merger excitement.
Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.
The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
GoPro Inc is a United States-based company that is principally engaged in designing and providing cameras, mounts, drones and appliances. The company outsources a part of manufacturing to third parties in China. The company sells products across the world through its direct sales channel, which generates over half of total revenue, and indirectly through its distribution channel. The company has presence, including in the Americas, Europe, Middle East, Africa, and Asia-Pacific, with the Americas contributing over half of total revenue.
Read more on GPRO →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →